Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer

NCT02990845 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT02990845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02990845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer
Lead sponsor
National Taiwan University Hospital
Phase
Phase 1/2
Overall status
Terminated
Start date
September 15, 2017
Completion date
August 16, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

premenopausal breast cancer